AstraZeneca PLC
AZNCF · PINK204.27
204.27
USD3.461.72%Дата
Тікери
Заголовок
Джерело
Abivax pares gain after denying AstraZeneca speculation
SeekingAlpha
Momentum traders are flagging several health care stocks that may be overheated heading into the new quarter. As of Feb. 18, 2026, elevated RSI readings suggest recent gains could be vulnerable to pullbacks despite strong headlines. AstraZeneca has surged roughly 14% over the https://t.co/eVMOTmA1TE
AstraZeneca profit climbs on cancer and heart drug demand
MarketWatch
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca
Cryptopolitan
AstraZeneca hails major breakthroughs with breast-cancer drugs
MarketWatch
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
MarketWatch
Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
CNBC
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
MarketWatch
China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca
SeekingAlpha
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
MarketWatch
AstraZeneca will invest US$50bn in the US to expand manufacturing and research
Forexlive
AstraZeneca shares show signs of life after successful trials of hypertension drug
MarketWatch
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
CNBC
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
SeekingAlpha
FibroGen sells China unit to AstraZeneca for $160 million
SeekingAlpha
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
CNBC
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
MarketWatch
AstraZeneca to pay up to $2 billion to license cardiovascular drug
MarketWatch
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
CNBC
AstraZeneca completes acquisition of Fusion Pharmaceuticals
SeekingAlpha
Ontario court approves AstraZeneca/Fusion acquisition plan
SeekingAlpha
Fusion shareholders give green light to AstraZeneca acquisition
SeekingAlpha
AstraZeneca to build $1.5 billion cancer drug manufacturing plant in Singapore - Reuters
Reuters
AstraZeneca will buy Fusion Pharmaceuticals for ~$2B
SeekingAlpha
AstraZeneca to expand rare disease pipeline with $1.05B Amolyt Pharma acquisition
SeekingAlpha
Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca
SeekingAlpha
Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled
SeekingAlpha
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
MarketWatch
AstraZeneca to buy Gracell Biotechnologies for $1.2 billion
SeekingAlpha
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
MarketWatch
Cytokinetics gains amid report of Novartis, AstraZeneca takeover interest
SeekingAlpha
AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal
SeekingAlpha
Icosavax enters agreement to be acquired by Astrazeneca
SeekingAlpha
AstraZeneca partners with AI company to find cure for cancer
CoinTelegraph
AstraZeneca and Absci Collaborate on AI-Driven Cancer Therapy Development
Cryptopolitan
Drug Giant AstraZeneca Launches Evinova to Quicken Clinical Trials
Decrypt
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
CNBC
AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
CNBC
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
MarketWatch
Часті питання
На що чекаєте?Почніть заробляти прибуток сьогодні
Інструменти
Ринки
Більше
Ресурси
Порівняти
Мобільний додаток для отримання прибутку
Відкрийте світ фінансів у вашому кишені
©
2026
Всі права захищені